Difference between revisions of "Berlin J, et al. Clin. Cancer Res. (2013) cited as Ref 606 in DOI: 10.1038/s41392-020-0110-5 (Q9869)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Publication Date (P100): 2013, #quickstatements; #temporary_batch_1590002823654)
(‎Created claim: Page(s) (P105): 258-267, #quickstatements; #temporary_batch_1590074839150)
 
(3 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Clin. Cancer Res.
Property / Published In Name String: Clin. Cancer Res. / rank
 +
Normal rank
Property / Volume
 +
19
Property / Volume: 19 / rank
 +
Normal rank
Property / title
 +
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English)
Property / title: A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English) / rank
 +
Normal rank
Property / Page(s)
 +
258-267
Property / Page(s): 258-267 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Berlin J, et al. Clin. Cancer Res. (2013) cited as Ref 606 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Berlin J
    0 references
    0 references
    2013
    0 references
    Clin. Cancer Res.
    0 references
    19
    0 references
    A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (English)
    0 references
    258-267
    0 references